

PU4828wo

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/101467 A1

(51) International Patent Classification⁷: **A61K 31/7076.**
31/7068, 47/38, A61P 31/14, 31/18

(74) Agents: **LEVY, David, J et al.**; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number: **PCT/US03/17347**

(81) Designated States (*international*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 June 2003 (03.06.2003)

(84) Designated States (*regional*): ARIPO patent (GH, GM,

(25) Filing Language: English

KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

(26) Publication Language: English

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

(30) Priority Data:

60/385,717 4 June 2002 (04.06.2002) US

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

(71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED [GB/GB]**; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

(72) Inventors: and

SE, SI, SK, TR), OAPI patent (BF, BJ, CI, CG, CI, CM,

(75) Inventors/Applicants (*for US only*): **CURRIE, Robin** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **GOODSON, Gary, Wayne** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/101467 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ABACAVIR AND LAMIVUDINE

(57) Abstract: A pharmaceutical composition comprising (1S, cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, in an amount which achieves antiviral efficacy, a process for the preparation of such a composition, and a method of inhibiting human immunodeficiency virus (HIV) which comprises administering such a composition to an HIV infected patient is disclosed.

Express Mail Label No.
EV 332063787 US

BEST AVAILABLE COPY